HopeStage
Back to all studies
CompletedNCT03745820

BIIB104 and Working Memory in Schizophrenia

About this titleRead the official source — NCT03745820

Researchers compared BIIB104 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Medication studyAges 18–55Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared BIIB104 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
Bentonville and 59 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: November 15, 2018
Recruitment status
Completed
Enrollment listed in the registry
195
Sponsor
Biogen
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, United Kingdom, Germany, ...
Age range
From 18 Years to 55 Years
Official registry ID
NCT03745820
Official title
Show the full official title

A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bentonville, United States · Culver City, United States · Garden Grove, United States

54 more locations
  • Lemon Grove, United States
  • Long Beach, United States
  • Montclair, United States
  • Oceanside, United States
  • Pico Rivera, United States
  • San Diego, United States
  • San Rafael, United States
  • Torrance, United States
  • New Haven, United States
  • Lauderhill, United States
  • Miami, United States
  • Tampa, United States
  • Atlanta, United States
  • Augusta, United States
  • Decatur, United States
  • Chicago, United States
  • Hoffman Estates, United States
  • Springfield, United States
  • Gaithersburg, United States
  • Grand Rapids, United States
  • Flowood, United States
  • St Louis, United States
  • Berlin, United States
  • Buffalo, United States
  • Cedarhurst, United States
  • Rochester, United States
  • Columbus, United States
  • North Canton, United States
  • Richardson, United States
  • San Antonio, United States
  • Kirkland, United States
  • Bad Homburg, Germany
  • Frankfurt am Main, Germany
  • Westerstede, Germany
  • Leipzig, Germany
  • Anan-shi, Japan
  • Ichikawa-shi, Japan
  • Kashihara-shi, Japan
  • Kawasaki-shi, Japan
  • Kita-gun, Japan
  • Kodaira-shi, Japan
  • Kumagaya-shi, Japan
  • Takasaki-shi, Japan
  • Yokosuka-shi, Japan
  • Santander, Spain
  • Majadahonda, Spain
  • Oviedo, Spain
  • Barcelona, Spain
  • Madrid, Spain
  • Salamanca, Spain
  • Seville, Spain
  • Oxford, United Kingdom
  • Lyne, United Kingdom
  • London, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared BIIB104 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Who is behind this study?

The study sponsor is Biogen.

Did this study involve medication?

Yes. The study involved medication, including BIIB104.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies